Epigenics Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 2

Epigenics General Information

Description

Developer of nutritional supplements designed to support health and longevity based on current aging and longevity research. The company offers products formulated with scientifically studied ingredients, focusing on purity, bioavailability, and evidence-based benefits, enabling health-conscious individuals seeking to optimize their well-being and lifespan to access advanced supplementation tailored to the latest scientific findings.

Contact Information

Website
www.epigenics.eu
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Lottumstrasse 13A
  • 10119 Berlin
  • Germany
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Vertical(s)
LOHAS & Wellness, E-Commerce, HealthTech
Corporate Office
  • Lottumstrasse 13A
  • 10119 Berlin
  • Germany

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Epigenics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 01-Oct-2023 Completed Generating Revenue
To view Epigenics’s complete valuation and funding history, request access »

Epigenics Patents

  • 7

    Total Documents Applications and Grants

  • Total Patents Families

  • 4

    Granted

  • 3

    Pending

  • Expiring in next 12 mo

Epigenics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
DE-202025004173-U1 Composition, dosage form and associated dietary supplement for reducing the sleep onset phase and improving the sleep-wake rhythm Active 25-Apr-2025
DE-202025004170-U1 Composition, dosage form and associated dietary supplement to support intestinal health Active 25-Apr-2025
DE-202025004171-U1 Composition, dosage form and associated dietary supplement to support women in menopause and/or perimenopause Active 25-Apr-2025
DE-102025114667-A1 Composition, dosage form and associated dietary supplement for maintaining and/or restoring mental performance and for stress reduction Pending 15-Apr-2025
DE-202025004192-U1 Composition, dosage form and associated dietary supplement for maintaining and/or restoring mental performance and for stress reduction Active 15-Apr-2025 A61P25/28
To view Epigenics’s complete patent history, request access »

Epigenics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Epigenics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Square One Foods Venture Capital Minority
Vealo Ventures Venture Capital Minority
To view Epigenics’s complete investors history, request access »

Ready to get started?

Request a free trial

Epigenics FAQs

  • When was Epigenics founded?

    Epigenics was founded in 2022.

  • Where is Epigenics headquartered?

    Epigenics is headquartered in Berlin, Germany.

  • What is the size of Epigenics?

    Epigenics has 5 total employees.

  • What industry is Epigenics in?

    Epigenics’s primary industry is Pharmaceuticals.

  • Is Epigenics a private or public company?

    Epigenics is a Private company.

  • What is Epigenics’s current revenue?

    The current revenue for Epigenics is .

  • Who are Epigenics’s investors?

    Square One Foods and Vealo Ventures have invested in Epigenics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process